The goal of this project was to establish the effect of alcohol consumption on the circulating levels of the adipose tissue derived protein C1q TNF Related Protein 3 (CTRP3). Adipose tissue secretes several adipokines, such as adiponectin and leptin, which exert a multitude of biological effects important for human health. However, adipose tissue is extremely sensitive to alcohol consumption, leading not only to disrupted fat storage, but also to disruptions in adipokine production. Changes to adipokine secretion could have widespread biological effects and potentially contribute to alcohol-induced ailments, such as alcoholic fatty liver disease (ALD). CTRP3 has been previously demonstrated to attenuate fatty liver disease, and suppression of CTRP3 with alcohol consumption could contribute to development of and progression to alcoholic fatty liver disease. To examine the effect of ethanol consumption on circulating adipokine levels, male and female mice were fed an ethanol containing diet (Lieber-DeCarli 5% (v/v) ethanol diet) for 10-days followed by a single gavage of 5 g/kg ethanol (the NIAAA model), or for 6-weeks with no binge added (chronic model). In female mice, adiponectin levels increased ~2-fold in both models of ethanol feeding, but in male mice increased adiponectin levels were only observed after chronic ethanol feeding. On the other hand, in female mice, circulating CTRP3 levels decreased by ~75% and ~50% in the NIAAA and chronic model, respectively, with no changes observed in the male mice in either feeding model. Leptin levels were unchanged with ethanol feeding regardless of model or sex of mice. Lastly, chronic ethanol feeding led to a significant increase in mortality (~50%) in female mice, with no difference in relative ethanol consumption. These findings indicate that ethanol consumption can dysregulate adipokine secretion, but that the effects vary by sex of animal, method of ethanol consumption, and adipokine examined. These findings also indicate that female mice are more sensitive to the chronic effects of ethanol than male mice. Notably, this is the first study to document the effects of ethanol consumption on the circulating levels of CTRP3. Understanding the impact of excessive alcohol consumption on adipokine production and secretion could identify novel mechanisms of alcohol-induced human disease. However, the mechanism responsible for the increased sensitivity remains elusive.
Citation: DeGroat AR, Fleming CK, Dunlay SM, Hagood KL, Moorman JP, Peterson JM (2018) The sex specific effect of alcohol consumption on circulating levels of CTRP3. PLoS ONE 13(11): e0207011. https://doi.org/10.1371/journal.pone.0207011
Editor: Andrey E. Ryabinin, Oregon Health and Science University, UNITED STATES
Received: May 23, 2018; Accepted: October 23, 2018; Published: November 7, 2018
Copyright: © 2018 DeGroat et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This work received support from the National Institute of Health, National Institute on Alcohol Abuse and Alcoholism R03AA023612, National Institute of Diabetes and Digestive and Kidney Diseases 1R15DK114740-01A1, and East Tennessee State University research development committee to JMP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
The detrimental effects of chronic alcohol abuse have been well-documented in the setting of established, long-term health conditions such as cardiovascular disease , respiratory distress , gastrointestinal dysfunction, alcoholic liver disease [3–6], cancer , and metabolic dysfunction . Excessive alcohol consumption not only causes initial injury via direct toxic effects (i.e. oxidative stress) to the individual tissues, but also results in secondary indirect injury through elevations in inflammatory cytokines and ectopic fat deposition [9, 10]. Although little can be done to prevent the acute toxic effects of alcohol consumption, understanding and reducing secondary alcohol-induced injury is a key component of treating the long-term health conditions associated with chronic alcohol consumption.
Adipose tissue is not only the primary location for the storage of excess lipids, but is also a major contributor to the production of circulating inflammatory cytokines . Furthermore, chronic alcohol consumption results in high levels of adipose-tissue oxidative stress, leading to elevations in inflammation and hyperlipolysis . Therefore, alcohol-induced disruptions to adipose tissue function, contribute to the wide-spread development of secondary alcohol-related health conditions. Females have a higher amount of adipose tissue (higher percent body fat), and this may account for the increased susceptibility of females to the chronic effects of alcohol [5, 7, 12–14].
In addition to the direct effects of alcohol on adipose tissue, alcohol consumption can also lead to disruptions in adipokine secretion. Adipokines are bioactive proteins secreted by adipose tissue, which can have significant endocrine effects on regulating human health and disease. Circulating levels of the most widely studied adipokines, leptin and adiponectin, are significantly affected by alcohol consumption [10, 15–29]. Leptin is primarily a satiety signal; therefore, its role in ethanol-related health effects is unclear. However, adiponectin stimulates fatty acid oxidation and inhibits both the activity and production of inflammatory cytokines [10, 30, 31], thus supporting our hypothesis that alcohol-induced disruptions to adipokine production can contribute to the development of alcoholic related disease.
In 2004, Wong et al identified a novel family of adipokines, referred to as Complement C1q Tumor Necrosis Factor-Related Proteins (CTRPs) [32, 33]. The initial characterization of these adipose tissue-derived CTRP factors demonstrates wide-ranging effects upon metabolism, inflammation, and survival-signaling [32–52]. As alcohol alters the expression of adiponectin [12, 18, 19, 26–28], we hypothesized that chronic alcohol abuse would also affect other adipokines, specifically CTRP3. We chose to look specifically at CTRP3 because it has previously been shown that overexpressing CTRP3 reduces both high-fat diet induced fatty liver, decreases the synthesis of triglycerides, and decreases circulating levels of the inflammatory cytokine TNF-α . Therefore, the purpose of this project was to establish the effects of alcohol on the circulating levels of CTRP3. The results of this study could produce a new understanding to the mechanism by which chronic alcohol consumption leads to ectopic fat deposition and other health related issues.
Forty female mice (C57BL/6) and thirty-seven male mice (C57BL/6) were used for this study. Mice were housed in polycarbonate cages on a 12-h light-dark photocycle with ad libitum access to water and food, except as specified. At the time points indicated, animals were anesthetized with isoflurane and euthanized via cardiac puncture. Serum samples were prepared according to manufacturer’s instructions (Sarstedt, Cat#41.1500.005). The gonadal fat pads were excised, snap frozen in liquid nitrogen, and stored at −80°C until further analysis. All animal procedures were conducted in accordance with institutional guidelines, and ethical approval was obtained from the University Committee on Animal Care (protocol #P151201; East Tennessee State University, Animal Welfare Assurance number is A3203-01). Animals were checked/weighed daily and euthanized (counted as dead), via CO2 inhalation, based on the presence of any of the following criteria for humane endpoints: unconsciousness, intractable seizures, labored breathing or respiratory distress, inability to ambulate or maintain upright position, diarrhea or constipation, or the inability to eat or drink.
Two independent ethanol feeding models were employed: The first model was the 11-day chronic plus binge model, also known as the NIAAA model . This model reportedly mimics hepatic steatosis and liver injury, which occurs in many alcoholic hepatitis patients (26). Briefly, 12-week old mice were acclimatized to a control liquid diet (Bio-serv; cat# F1259SP) for 4 days followed by 10 days on the Lieber-DeCarli ethanol diet (5% v/v ethanol; Bio-serv; cat# F1258SP) ad libitum. On the morning of the 11th day (1 hour into light cycle) food was removed and replaced with water and the mice were given a single gavage of ethanol (5 g kg-1). After gavage, cages were placed on heating pads to prevent hypothermia, as described . Nine hours post gavage, mice were anesthetized with isoflurane, until the absence of reflex was observed, and then euthanized by exsanguination, and tissue/serum samples were collected and processed for analysis.
In the second model (chronic model), 8-week old male and 12-week old female mice were acclimatized to a liquid diet ad libitum, without the addition of alcohol for 1-week and then gradually transitioned from 1–5% Lieber-DeCarli ethanol diet (v/v ethanol) over the course of the next 2 weeks, then maintained on 5% ethanol (v/v ethanol) for the remaining 4 weeks. This feeding protocol is believed to reflect chronic ethanol abuse, beginning with low volumes and increasing over time . On the morning of the final day, food was removed, and mice were fasted 9 hours, anesthetized with isoflurane until the absence of reflex was observed, and the euthanized by exsanguination, and tissue/serum samples were collected and processed for analysis. The 9-hour time point was selected to be consistent with the NIAAA model protocol .
Control fed mice were placed on an ethanol free isocaloric control diet (Bio-serv; cat# F1259SP) supplemented with maltose dextrin (to match the calories of ethanol), for use as experimental controls. Food intake and body weight were measured daily and mice on the control diet had their food intake limited to match the average total intake for the previous day of the corresponding group of ETOH-fed mice. Mice were group housed 2–4 mice per cage and the food intake was calculated as total/mouse. Food intake and food intake normalized to body weight data were measured and calculated daily for each mouse. The combined average daily values for each mouse were then compared.
Serum samples were diluted 1:5 in assay buffer (50 mM Tris HCl, pH 8.0, 150 mM NaCl, 0.1% Triton x-100, 0.5% sodium deoxycholate, 0.1% SDS), plus the addition of protease inhibitors (Bimake Cat#B14001). Afterwards an equal volume of 2x SDS loading buffer (final concentration: 1% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.004% bromophenol blue, 0.125 M Tris HCl, pH 6.8) was added and the samples were denatured for 5 minutes at 95°C. For each sample 1 μl serum was separated by gel electrophoresis (BioRad; cat#456–1046) and transferred to a nitrocellulose membrane (BioRad; Cat#162–0115), according the manufacturer’s instructions. To confirm appropriate protein migration a protein standard was loaded with each blot (BioRad cat#1610374 or Thermo Scientific cat#26616). Membranes were blocked in 2% non-fat milk and probed with primary antibodies: CTRP3 (R and D Systems Cat# AF2436, RRID:AB_2067713) and Adiponectin (R and D Systems Cat# MAB1119, RRID:AB_2305045). After incubation with primary antibodies membranes were washed and probed with appropriate HRP-labeled secondary antibodies: Rabbit anti-goat (Thermo Fisher Scientific Cat# 31402, RRID:AB_228395) and rabbit anti-rat (Thermo Fisher Scientific Cat# PA1-28786, RRID:AB_10983740). Chemiluminescence signals were visualized with Millipore (Cat# 17010A2). Quantification of signal intensity was performed using Alphaview Software (Alpha Innotech). Due to limited number of wells on a western blot and to avoid blot-to-blot comparisons an n = 6 was used for immunoblot analysis.
RNA was isolated according to commercial assay following manufacturer’s instructions (Direct-zol Cat# R2070). Isolated RNA was eluted in 50 μl RNase-free water; purity (RIN ≥ 7.0) and concentrations were confirmed by microfluidic capillary electrophoresis (Agilent RNA 6000 Nano kit, #5067–1511, Agilent Technologies). 1 μg RNA was reverse transcribed according to manufacturer’s instructions (Promega, Cat#A5001).
Quantitative real-time PCR
A 10-fold dilution series of DNA amplicons generated from a prepared sample was employed as a standard curve for each gene of interest, and the qPCR efficiency was determined for each gene (Bio-Rad Cfx thermocycler). All qRT-PCR primers displayed a coefficient of correlation greater than 0.95 and efficiencies between 90% and 110%. Primer sequences are listed in Table 1. Briefly, 25 ng of cDNA was incubated in SYBR Green qPCR Master mix (Bimake.com, Cat# B21203) for an initial denaturation at 95°C for 10 min, followed by 40 PCR cycles each consisting of 95°C for 15 s, and 60°C for 1 min. After the last cycle specificity of amplification products were confirmed by analyzing melting curve profiles for primers and products. Data is reported as copy number normalized to the geometric mean of the reference genes Beta-actin (Actb) and Hypoxanthine-guanine phosphoribosyltransferase (Hprt1).
Serum transaminases and pro-inflammatory cytokines
Interleukin-6 (IL-6), Tumor necrosis factor alpha (TNF), Plasminogen activator inhibitor-1 (PAI-1) and leptin were measured using the Bio-Plex Multiplex Immunoassay System according to manufacturer’s instructions (Bio-rad Cat# 171G5023M, 171I50001, 171G5007M). Serum Alanine Aminotransferase (ALT) concentrations were determined using commercially available assays according to manufacturer’s directions (ALT, Fisher Diagnostics Cat#TR71121). Specific assay working ranges, coefficients of variation, and limits of detection are listed in the supplemental data (S1 Table). Any value below the detectable assay working range was assigned the value equivalent to the lower limit of quantification.
Hepatic lipid analysis
Lipids were extracted as described by Bligh and Dyer and as previously performed . Briefly, liver samples were weighed and homogenized in phosphate-buffered saline (10 ml/g tissue), followed by the addition of 1:2 (vol/vol) chloroform-methanol (3.75 ml/ml of sample homogenate). Next, chloroform was added (1.25 ml/ml of sample homogenate), followed by a final addition of distilled water (1.25 ml/ml of sample homogenate). Samples were vortexed for 30s between each step. Samples were then centrifuged (1,100 g for 10 min at room temperature) to give a two-phase solution (aqueous phase on top and organic phase below). The lower phase was collected with a glass pipette with gentle positive pressure (as to not disturb the upper phase), dried under nitrogen gas at 60°C, and was dissolved in tert-butyl alcohol-Triton X-100 (3:2 vol/vol) solution. Triglycerides were quantified via colorimetric assay according to manufacturer’s directions (Infinity Triglycerides, Fisher Diagnostics, Cat# TR22421).
Descriptive statistics (mean and standard deviations) were calculated for all measured variables. As the NIAAA and chronic feeding models were not performed concurrently, each sex and model were analyzed independently. Final Body weight, average daily food intake, and average daily food intake normalized to daily body weight were analyzed by one-way ANOVA followed by Tukey's multiple comparisons test. All remaining analysis was performed within sex and within diet. Survival curve was determined by log-rank (Mantel-Cox) test. A D'Agostino & Pearson omnibus normality test was used to test for normal distribution in serum analytes. An Unpaired t test was used for normally distributed data and a Mann Whitney U test was used for non-parametric data analysis (TNF-α) to compare data between control and ethanol fed groups within each sex and feeding model for all other variables. All statistical analysis was performed by Graphpad Prism 6, results of ANOVA (F statistics and degrees of freedom) are attached as supplemental data (S1 File).
No differences in body weight between ethanol and control fed groups were observed. There was a slightly higher food intake for the ethanol fed NIAAA males and the chronic females than their corresponding control fed groups. However, when normalized to body mass, no differences were observed in average daily food intake (ethanol consumption) among ethanol fed and control fed male or female mice (Table 2). Both ethanol feeding protocols demonstrated an increase in hepatic triglycerides and ALT levels. Circulating levels of the transaminase ALT were measured as a marker of hepatic injury and serum cytokines were measured as a marker of systemic inflammation. The cytokine IL-6 was elevated in both feeding models for female mice but was not different in the male mice. The levels of the proinflammatory cytokine TNF-α were below the lower limit of detection in almost all control fed mice. Whereas, in the NIAAA model of ethanol feeding TNF-α was detected in 4/6 females and 6/9 males and in the chronic model of ethanol feeding TNF-α was observed in 9/10 females but only in 3/10 males. Lastly, PAI-1 levels were elevated in both male and female mice regardless of feeding model used. Means, standard deviations and range for all serum values are reported in Table 2.
All animals on the NIAAA feeding protocol survived through the end of the experiment. Unexpectedly, with 6-weeks of ethanol feeding the female mice suffered 50% mortality compared with a non-significant difference in mortality rate in identically treated male mice (Fig 1). Mice that died prior to completion of the feeding protocol were removed from the study, resulting in a final count of 10 chronic ethanol fed mice for each sex which were used for subsequent analysis.
The survival curve was plotted for female (A) and male (B) mice on the chronic ethanol feeding model. Data are reported as percent of total, * = p < 0.05 ETOH vs Con. Abbreviations: Con-F, pair-fed female; ETOH-F, ethanol fed female; Con-M, pair-fed male; ETOH-M, ethanol fed male.
In response to the NIAAA model, female mice fed ethanol had an ~200% increase in circulating levels of adiponectin (Fig 2A) and a ~75% decrease in CTRP3 (Fig 2C). However, ethanol treatment in the male mice led to no change in circulating adiponectin (Fig 2A) or CTRP3 (Fig 2C) levels. With chronic ethanol feeding, circulating adiponectin levels doubled in both the male and female mice (Fig 2B), but again CTRP3 levels were only reduced in the female mice. Interestingly, although leptin levels varied widely, they were not different between control and ethanol fed mice regardless of ethanol feeding model examined (Fig 2E and 2F).
Circulating adiponectin and CTRP3 levels were determined by immunoblot in serum collected from ethanol fed mice (n = 6). Circulating leptin levels were determined using multiplex serum analysis. Data are reported as mean ± SD. Male and female blots were performed and analyzed independently, and values were normalized to control fed within each sex. * = p < 0.05 ETOH vs Con. Abbreviations: Con-F, pair-fed female; ETOH-F, ethanol fed female; Con-M, pair-fed male; ETOH-M, ethanol fed male; NIAAA, National Institute on Alcohol Abuse and Alcoholism. Representative immunoblot images are shown, full membrane images are attached as supplemental data (S1 and S2 Figs).
Adipokine gene expression
Gonadal adipose gene expression was analyzed to determine if differences in serum could be contributed to changes in tissue expression. However, no differences were observed in adiponectin or CTRP3 gene expression (Fig 3), indicating that changes to gene expression, at least in the gonadal fat pads, were not responsible for the changes in circulating adipokine levels.
Gonadal adipokine gene expression was measured in chronically ethanol fed mice. Data are reported as mean of log starting quantity per 25 ng RNA (A-D) or geometric mean ± SD. Abbreviations: Con-F, pair-fed female; ETOH-F, ethanol fed female; Con-M, pair-fed male; ETOH-M, ethanol fed male. Cq values for each sample are shown in supplemental S2 Table.
The primary finding of this study is that excessive ethanol consumption effects the concentration of circulating adipokines levels, but not uniformly. Briefly, with alcohol consumption adiponectin levels increased and CTRP3 levels decreased, whereas no significant difference in leptin levels was observed.
The secondary and unanticipated finding of this study is that female mice have a higher mortality rate in response to chronic alcohol feeding male mice. Although increase sensitivity to ethanol feeding has been repeatedly noted in the literature to our knowledge this is the first documentation of mortality with identically treated male and female mice [5, 13, 56]. In this study, male and female mice consumed similar amounts of ethanol, normalized to body weight; however, female mice had significant inflammation (elevations in TNF-α and IL-6) as well as mortality. Conversely, there was no difference in mortality between control and ethanol fed male mice. Interestingly, there was no difference in mortality between ethanol fed male and female mice within the first 4 weeks of ethanol feeding. These data indicate that the female mice are more sensitive to the chronic effects of ethanol consumption. It is important to note that ethanol consumption led to increased levels of PAI-1, indicating in both sexes that alcohol consumption leads to tissue damage and disruptions to overall tissue homeostasis .
Adiponectin was one the first adipokines discovered and widely studied. Circulating levels of adiponectin have been documented to be affected by alcohol consumption, although to what extent alcohol alters this protein is unclear. In brief, adiponectin levels have been shown to be suppressed [18, 24], not different , or elevated [12, 18, 19, 26–28, 58] in response to alcohol consumption. It is suspected that oxidative stress induced by acute alcohol exposure reduces the secretion of adiponectin , indicating that time since last dose of ethanol can affect results. As our mice were 9-hrs removed from the last ethanol exposure, any acute suppression of adiponectin secretion that may have occurred would not have been observed. On the other hand, chronic alcohol abuse has demonstrated positive associations between circulating adiponectin levels and the severity of liver damage in cases of cirrhosis [10, 59–61]. Our data supports the finding that circulating adiponectin levels increase with both NIAAA and chronic alcohol consumption [12, 18, 19, 26–28]. Combined, these data indicate that activating adiponectin and adiponectin mediated signaling pathways may not be a successful strategy for the prevention/treatment of alcoholic liver disease, as its levels are already increased with, at least in some models of, chronic ethanol exposure.
Ethanol feeding reduced circulating CTRP3 levels in female, but not male, mice in response to both the NIAAA and chronic feeding model. Alcoholic cirrhosis occurs at a higher rate in female alcoholic patients, at an earlier age, and with a lower proportional amount of alcohol consumption [5, 12, 13]. As CTRP3 levels are selectively reduced in ethanol fed female mice, this provides a novel mechanism to explore the increased susceptibility of females to alcoholic cirrhosis. Our previous work has shown that CTRP3 acts directly on liver tissue to stimulate lipid oxidation and attenuate both diet-induced and alcoholic fatty liver disease [38, 55]. In support of this, CTRP3 levels are found to be lower in human patients with diet-induced hepatic steatosis, or non-alcoholic fatty liver disease . Further, our lab as well as others have shown that CTRP3 has been shown to prevent inflammation [48, 49, 52, 63, 64]. Chronic alcohol consumption disrupts lipid synthesis which leads to the buildup of hepatic lipids, resulting in alcoholic fatty liver and eventually alcoholic cirrhosis [5, 9, 13], the leading causes of liver failure and a leading cause of death in the Unites States [5, 13, 14, 56]. Thus, there has been renewed interest in developing effective therapeutic strategies to prevent alcoholic fatty liver disease [4, 6, 9, 13, 65, 66]. Our data, combined with the finding that CTRP3 prevents alcohol-induced fatty liver disease , identifies CTRP3 as an ideal candidate to develop novel treatments for alcoholic fatty liver disease.
Sex specific effects of ethanol
For at least 30 years it has been documented that females have an increased morbidity (i.e. alcoholic cirrhosis) with alcohol consumption compared with men, starting at an earlier age and with a lower duration and amount of relative alcohol consumption [67–70]. These findings have been independently confirmed multiple times throughout the literature [5, 12, 13, 56, 67–69, 71–79]. To make matter worse, even after drinking is ceased, females have a worse prognosis than males, indicating sexual dimorphism in the long-term effects of chronic alcohol abuse [68, 69]. Further, in animal experiments with identical feeding protocols there is a significant increase in systemic inflammation, liver inflammation, and hepatic fibrosis in female mice [12, 53, 72, 73, 80], which is in agreement with the results of this study.
Although the mechanisms responsible for the increased sensitivity of females to alcohol remain elusive, there evidence to link these effects to presence of certain female sex hormones. For example, with chronic alcohol consumption endotoxins are released from the gut into the circulation. When animals are exposed to high levels of female sex hormones combined with endotoxins the immune cells generate ~300% more inflammatory cytokines than in response to endotoxins alone [72, 77, 79, 81]. This hyper-activation of the immune system exacerbates any ethanol-induced dysfunction. Interestingly, if the sex hormones are added to isolated macrophages no endotoxin sensitization occurs, indicating a non-direct pathway [72, 77, 79]. CTRP3 is a unique and exciting circulating adipokine as it prevents both endotoxin activation of macrophages [47–49, 52] and alcohol-induced hepatic triglyceride accumulation, at least in male mice . Combined with the data from this manuscript, demonstrating that ethanol feeding leads to a significant reduction in circulating CTRP3 levels in female mice, the ethanol-induced reduction in circulating CTRP3 levels are a potential mechanism for the increased hepatic sensitivity to alcohol in females. However, this premise as well as the effects of sex hormones on circulating CTRP3 levels both require further study.
All of our data is from a 9-hour fasted time-point, which is sufficient to demonstrate baseline data, but does not demonstrate the metabolic changes to the post-prandial state of these animals. Ethanol ingestion could acutely suppress the secretion of adipokines, such as adiponectin, which could explain the discrepancy among adiponectin levels reported in the literature. Further, although we did not observe significant differences in circulating leptin levels, the unexpectantly high variability combined with our small sample size obscured potential difference between groups. We also only harvested gonadal adipose tissue for RNA analysis, and did not determine adipose tissue weight. It is possible that gene expression differences in other adipose tissue compartments (i.e. subcutaneous) may contribute to changes to circulating adipokine expression or that changes to total amount of adipose tissue could affect circulating CTRP3 levels. Future studies should examine the effects of alcohol on total amount of adipose tissue as well as gene expression at various adipose tissue depots. Lastly, as the animals were group housed, we were unable to account for the exact amount of diet consumed by each individual mouse which could increase the variability in the data analysis. Another source of variability is that because mice were housed 2–4 per cage and died at an uneven rate, the amount of diet (and ethanol) consumed per mouse can only be estimated.
Since the discovery of leptin and adiponectin, research into understanding the role of adipokines in human health has become a popular topic. This study demonstrates that sex and mode of ethanol exposure can significantly influence the results, indicating that the role of alcohol on adipokines should be studied via multiple models. Lastly, we have identified the sex specific, alcohol-induced reduction in CTRP3 as a potential mechanism for the increased susceptibility of females to alcoholic cirrhosis. These findings warrant further study.
S1 Fig. Supporting data for Fig 2A and 2C, circulating adipokines in the NIAAA model of ethanol feeding.
Full membrane of ponceau red stains (A, C, E, G) and the chemiluminescence images (B, D, F, H) are shown for proteins as indicated. The protein standards (Cat# 161–0374 or 26612) have been labeled with corresponding protein molecular weights. All samples on the blot were analyzed, box indicates representative subset shown in figure. ETOH samples are indicated with a bar under the bands of interest and control samples are left unmarked.
S2 Fig. Supporting data for Fig 2B and 2D, circulating adipokines in the chronic model of ethanol feeding.
Full membrane of ponceau red stains (A, C, E, G) and the chemiluminescence images (B, D, F, H) are shown for proteins as indicated. The protein standards (Cat# 161–0374 or 26612) have been labeled with corresponding protein molecular weights. All samples on the blot were analyzed, box indicates representative subset shown in figure. ETOH samples are indicated with a bar under the bands of interest and control samples are left unmarked.
S3 Fig. CTRP3 antibody specificity.
To test the specificity of the CTRP3 antibody we used measured supernant from HEK293 cell culture transfected with expression plasmid to express CTRP1, CTRP2, or CTRP3. This test showed the CTRP3 antibody used in the study is specific for detecting CTRP3 protein detecting a band ~25kDa.
S1 Table. Assay working ranges.
Specific assay working ranges, coefficients of variation, and limits of detection are listed for multiplex and ALT assay.
S2 Table. qPCR raw data.
Raw Cq values and geometric means for adiponectin, CTRP3 are reported. In addition Cq values for reference genes HPRT and Actin for each sample are reported.
- 1. Matsumoto C, Miedema MD, Ofman P, Gaziano JM, Sesso HD. An expanding knowledge of the mechanisms and effects of alcohol consumption on cardiovascular disease. J Cardiopulm Rehabil Prev. 2014;34(3):159–71. pmid:24667667.
- 2. Baumeister SE, Finger JD, Glaser S, Dorr M, Markus MR, Ewert R, et al. Alcohol consumption and cardiorespiratory fitness in five population-based studies. Eur J Prev Cardiol. 2017:2047487317738594. pmid:29056079.
- 3. Baraona E, Lieber CS. Effects of ethanol on lipid metabolism. J Lipid Res. 1979;20(3):289–315. pmid:87483.
- 4. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011;141(5):1572–85. pmid:21920463; PubMed Central PMCID: PMCPMC3214974.
- 5. Rehm J, Taylor B, Mohapatra S, Irving H, Baliunas D, Patra J, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010;29(4):437–45. pmid:20636661.
- 6. Stickel F, Seitz HK. Alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol. 2010;24(5):683–93. pmid:20955970.
- 7. Choi YJ, Lee DH, Han KD, Kim HS, Yoon H, Shin CM, et al. The relationship between drinking alcohol and esophageal, gastric or colorectal cancer: A nationwide population-based cohort study of South Korea. PLoS One. 2017;12(10):e0185778. pmid:28973012; PubMed Central PMCID: PMCPMC5626486.
- 8. Yoo MG, Kim HJ, Jang HB, Lee HJ, Park SI. The Association between Alcohol Consumption and beta-Cell Function and Insulin Sensitivity in Korean Population. Int J Environ Res Public Health. 2016;13(11). pmid:27854254; PubMed Central PMCID: PMCPMC5129343.
- 9. Parker R, Kim SJ, Gao B. Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations. Nat Rev Gastroenterol Hepatol. 2017. pmid:28930290.
- 10. Steiner JL, Lang CH. Alcohol, Adipose Tissue and Lipid Dysregulation. Biomolecules. 2017;7(1). pmid:28212318; PubMed Central PMCID: PMCPMC5372728.
- 11. Kema VH, Mojerla NR, Khan I, Mandal P. Effect of alcohol on adipose tissue: a review on ethanol mediated adipose tissue injury. Adipocyte. 2015;4(4):225–31. pmid:26451277; PubMed Central PMCID: PMCPMC4573182.
- 12. Fulham MA, Mandrekar P. Sexual Dimorphism in Alcohol Induced Adipose Inflammation Relates to Liver Injury. PLoS One. 2016;11(10):e0164225. pmid:27711160; PubMed Central PMCID: PMCPMC5053524.
- 13. Nagy LE, Ding WX, Cresci G, Saikia P, Shah VH. Linking Pathogenic Mechanisms of Alcoholic Liver Disease With Clinical Phenotypes. Gastroenterology. 2016;150(8):1756–68. pmid:26919968; PubMed Central PMCID: PMCPMC4887335.
- 14. Lozano R, al. e. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128. pmid:23245604.
- 15. He Z, Li M, Zheng D, Chen Q, Liu W, Feng L. Adipose tissue hypoxia and low-grade inflammation: a possible mechanism for ethanol-related glucose intolerance? Br J Nutr. 2015;113(9):1355–64. pmid:25989996.
- 16. Hiney JK, Dearth RK, Lara F, 3rd, Wood S, Srivastava V, Les Dees W. Effects of ethanol on leptin secretion and the leptin-induced luteinizing hormone (LH) release from late juvenile female rats. Alcohol Clin Exp Res. 1999;23(11):1785–92. pmid:10591595.
- 17. Obradovic T, Meadows GG. Chronic ethanol consumption increases plasma leptin levels and alters leptin receptors in the hypothalamus and the perigonadal fat of C57BL/6 mice. Alcohol Clin Exp Res. 2002;26(2):255–62. pmid:11964566.
- 18. Yu HC, Li SY, Cao MF, Jiang XY, Feng L, Zhao JJ, et al. Effects of chronic ethanol consumption on levels of adipokines in visceral adipose tissues and sera of rats. Acta Pharmacol Sin. 2010;31(4):461–9. pmid:20208553; PubMed Central PMCID: PMCPMC4007662.
- 19. Pravdova E, Macho L, Fickova M. Alcohol intake modifies leptin, adiponectin and resistin serum levels and their mRNA expressions in adipose tissue of rats. Endocr Regul. 2009;43(3):117–25. pmid:19817506.
- 20. Szkudelski T, Bialik I, Szkudelska K. Adipocyte lipolysis, hormonal and metabolic changes in ethanol-drinking rats. J Anim Physiol Anim Nutr (Berl). 2004;88(7–8):251–8. pmid:15274689.
- 21. Rojdmark S, Calissendorff J, Brismar K. Alcohol ingestion decreases both diurnal and nocturnal secretion of leptin in healthy individuals. Clin Endocrinol (Oxf). 2001;55(5):639–47. pmid:11894976.
- 22. Calissendorff J, Brismar K, Rojdmark S. Is decreased leptin secretion after alcohol ingestion catecholamine-mediated? Alcohol Alcohol. 2004;39(4):281–6. pmid:15208157.
- 23. Otaka M, Konishi N, Odashima M, Jin M, Wada I, Matsuhashi T, et al. Effect of alcohol consumption on leptin level in serum, adipose tissue, and gastric mucosa. Dig Dis Sci. 2007;52(11):3066–9. pmid:17406835.
- 24. Chen X, Sebastian BM, Nagy LE. Chronic ethanol feeding to rats decreases adiponectin secretion by subcutaneous adipocytes. Am J Physiol Endocrinol Metab. 2007;292(2):E621–8. pmid:17047161; PubMed Central PMCID: PMCPMC1794258.
- 25. Strbak V, Benicky J, Macho L, Jezova D, Nikodemova M. Four-week ethanol intake decreases food intake and body weight but does not affect plasma leptin, corticosterone, and insulin levels in pubertal rats. Metabolism. 1998;47(10):1269–73. pmid:9781633.
- 26. Tan X, Sun X, Li Q, Zhao Y, Zhong W, Sun X, et al. Leptin deficiency contributes to the pathogenesis of alcoholic fatty liver disease in mice. Am J Pathol. 2012;181(4):1279–86. pmid:22841822; PubMed Central PMCID: PMCPMC3463622.
- 27. Imhof A, Plamper I, Maier S, Trischler G, Koenig W. Effect of drinking on adiponectin in healthy men and women: a randomized intervention study of water, ethanol, red wine, and beer with or without alcohol. Diabetes Care. 2009;32(6):1101–3. pmid:19244090; PubMed Central PMCID: PMCPMC2681019.
- 28. Sierksma A, Patel H, Ouchi N, Kihara S, Funahashi T, Heine RJ, et al. Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care. 2004;27(1):184–9. pmid:14693987.
- 29. Tang H, Sebastian BM, Axhemi A, Chen X, Hillian AD, Jacobsen DW, et al. Ethanol-induced oxidative stress via the CYP2E1 pathway disrupts adiponectin secretion from adipocytes. Alcohol Clin Exp Res. 2012;36(2):214–22. pmid:21895711; PubMed Central PMCID: PMCPMC3235233.
- 30. Ohashi K, Shibata R, Murohara T, Ouchi N. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol Metab. 2014;25(7):348–55. pmid:24746980.
- 31. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746–9. pmid:7592907.
- 32. Wong GW, Wang J, Hug C, Tsao TS, Lodish HF. A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci U S A. 2004;101(28):10302–7. pmid:15231994; PubMed Central PMCID: PMCPMC478567.
- 33. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol. 1998;8(6):335–8. pmid:9512423.
- 34. Byerly MS, Petersen PS, Ramamurthy S, Seldin MM, Lei X, Provost E, et al. C1q/TNF-related protein 4 (CTRP4) is a unique secreted protein with two tandem C1q domains that functions in the hypothalamus to modulate food intake and body weight. J Biol Chem. 2014;289(7):4055–69. pmid:24366864; PubMed Central PMCID: PMCPMC3924272.
- 35. Petersen PS, Wolf RM, Lei X, Peterson JM, Wong GW. Immunomodulatory roles of CTRP3 in endotoxemia and metabolic stress. Physiol Rep. 2016;4(5). pmid:26997632; PubMed Central PMCID: PMCPMC4823594.
- 36. Peterson JM, Aja S, Wei Z, Wong GW. CTRP1 protein enhances fatty acid oxidation via AMP-activated protein kinase (AMPK) activation and acetyl-CoA carboxylase (ACC) inhibition. J Biol Chem. 2012;287(2):1576–87. pmid:22086915; PubMed Central PMCID: PMCPMC3256898.
- 37. Peterson JM, Seldin MM, Tan SY, Wong GW. CTRP2 overexpression improves insulin and lipid tolerance in diet-induced obese mice. PLoS One. 2014;9(2):e88535. pmid:24586339; PubMed Central PMCID: PMCPMC3930646.
- 38. Peterson JM, Seldin MM, Wei Z, Aja S, Wong GW. CTRP3 attenuates diet-induced hepatic steatosis by regulating triglyceride metabolism. Am J Physiol Gastrointest Liver Physiol. 2013;305(3):G214–24. pmid:23744740; PubMed Central PMCID: PMCPMC3742855.
- 39. Peterson JM, Wei Z, Seldin MM, Byerly MS, Aja S, Wong GW. CTRP9 transgenic mice are protected from diet-induced obesity and metabolic dysfunction. Am J Physiol Regul Integr Comp Physiol. 2013;305(5):R522–33. pmid:23842676; PubMed Central PMCID: PMCPMC3763026.
- 40. Peterson JM, Wei Z, Wong GW. C1q/TNF-related protein-3 (CTRP3), a novel adipokine that regulates hepatic glucose output. J Biol Chem. 2010;285(51):39691–701. pmid:20952387; PubMed Central PMCID: PMCPMC3000950.
- 41. Seldin MM, Tan SY, Wong GW. Metabolic function of the CTRP family of hormones. Rev Endocr Metab Disord. 2014;15(2):111–23. pmid:23963681; PubMed Central PMCID: PMCPMC3931758.
- 42. Wei Z, Peterson JM, Wong GW. Metabolic regulation by C1q/TNF-related protein-13 (CTRP13): activation OF AMP-activated protein kinase and suppression of fatty acid-induced JNK signaling. J Biol Chem. 2011;286(18):15652–65. pmid:21378161; PubMed Central PMCID: PMCPMC3091174.
- 43. Wei Z, Seldin MM, Natarajan N, Djemal DC, Peterson JM, Wong GW. C1q/tumor necrosis factor-related protein 11 (CTRP11), a novel adipose stroma-derived regulator of adipogenesis. J Biol Chem. 2013;288(15):10214–29. pmid:23449976; PubMed Central PMCID: PMCPMC3624406.
- 44. Wolf RM, Lei X, Yang ZC, Nyandjo M, Tan SY, Wong GW. CTRP3 deficiency reduces liver size and alters IL-6 and TGFbeta levels in obese mice. Am J Physiol Endocrinol Metab. 2016;310(5):E332–45. pmid:26670485; PubMed Central PMCID: PMCPMC4773650.
- 45. Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Ge G, Spooner E, Hug C, et al. Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin. FASEB J. 2009;23(1):241–58. pmid:18787108; PubMed Central PMCID: PMCPMC2626616.
- 46. Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Revett T, Gimeno R, Lodish HF. Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J. 2008;416(2):161–77. pmid:18783346; PubMed Central PMCID: PMCPMC3936483.
- 47. Hofmann C, Chen N, Obermeier F, Paul G, Buchler C, Kopp A, et al. C1q/TNF-related protein-3 (CTRP-3) is secreted by visceral adipose tissue and exerts antiinflammatory and antifibrotic effects in primary human colonic fibroblasts. Inflamm Bowel Dis. 2011;17(12):2462–71. pmid:21351204.
- 48. Kopp A, Bala M, Buechler C, Falk W, Gross P, Neumeier M, et al. C1q/TNF-related protein-3 represents a novel and endogenous lipopolysaccharide antagonist of the adipose tissue. Endocrinology. 2010;151(11):5267–78. pmid:20739398.
- 49. Kopp A, Bala M, Weigert J, Buchler C, Neumeier M, Aslanidis C, et al. Effects of the new adiponectin paralogous protein CTRP-3 and of LPS on cytokine release from monocytes of patients with type 2 diabetes mellitus. Cytokine. 2010;49(1):51–7. pmid:19955001.
- 50. Schmid A, Kopp A, Aslanidis C, Wabitsch M, Muller M, Schaffler A. Regulation and function of C1Q/TNF-related protein-5 (CTRP-5) in the context of adipocyte biology. Exp Clin Endocrinol Diabetes. 2013;121(5):310–7. pmid:23430573.
- 51. Schmid A, Kopp A, Hanses F, Bala M, Muller M, Schaffler A. The novel adipokine C1q/TNF-related protein-3 is expressed in human adipocytes and regulated by metabolic and infection-related parameters. Exp Clin Endocrinol Diabetes. 2012;120(10):611–7. pmid:23174996.
- 52. Schmid A, Kopp A, Hanses F, Karrasch T, Schaffler A. C1q/TNF-related protein-3 (CTRP-3) attenuates lipopolysaccharide (LPS)-induced systemic inflammation and adipose tissue Erk-1/-2 phosphorylation in mice in vivo. Biochem Biophys Res Commun. 2014;452(1):8–13. pmid:24996172.
- 53. Bertola A, Mathews S, Ki SH, Wang H, Gao B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc. 2013;8(3):627–37. pmid:23449255; PubMed Central PMCID: PMCPMC3788579.
- 54. Cohen JI, Roychowdhury S, McMullen MR, Stavitsky AB, Nagy LE. Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in mice. Gastroenterology. 2010;139(2):664–74, 74 e1. pmid:20416309; PubMed Central PMCID: PMCPMC3273045.
- 55. Trogen G, Bacon J, Li Y, Wright GL, Degroat A, Hagood KL, et al. Transgenic overexpression of CTRP3 prevents alcohol-induced hepatic triglyceride accumulation. Am J Physiol Endocrinol Metab. 2018. pmid:29763374.
- 56. Shoreibah M, Raff E, Bloomer J, Kakati D, Rasheed K, Kuo YF, et al. Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas. Ann Hepatol. 2016;15(2):183–9. pmid:26845595.
- 57. Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol. 2012;227(2):493–507. pmid:21465481; PubMed Central PMCID: PMCPMC3204398.
- 58. Lee Y, Kwon DJ, Kim YH, Ra M, Heo SI, Ahn WG, et al. HIMH0021 attenuates ethanol-induced liver injury and steatosis in mice. PLoS One. 2017;12(11):e0185134. pmid:29091708; PubMed Central PMCID: PMCPMC5665428.
- 59. Tietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab. 2004;287(1):E82–9. pmid:15010338.
- 60. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112(1):91–100. pmid:12840063; PubMed Central PMCID: PMCPMC162288.
- 61. You M, Considine RV, Leone TC, Kelly DP, Crabb DW. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology. 2005;42(3):568–77. pmid:16108051; PubMed Central PMCID: PMCPMC1398076.
- 62. Zhang J, Zhang B, Cheng Y, Xu J. Low serum CTRP3 levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Cytokine. 2017. pmid:29113741.
- 63. Compton SA, Cheatham B. CTRP-3: blocking a toll booth to obesity-related inflammation. Endocrinology. 2010;151(11):5095–7. pmid:20962058.
- 64. Li Y, Wright GL, Peterson JM. C1q/TNF-Related Protein 3 (CTRP3) Function and Regulation. Compr Physiol. 2017;7(3):863–78. pmid:28640446.
- 65. Sanyal AJ. Novel therapeutic targets for steatohepatitis. Clin Res Hepatol Gastroenterol. 2015;39 Suppl 1:S46–50. pmid:26160474.
- 66. Eguchi A, Povero D, Alkhouri N, Feldstein AE. Novel therapeutic targets for nonalcoholic fatty liver disease. Expert Opin Ther Targets. 2013;17(7):773–9. pmid:23600493.
- 67. Ashley MJ, Olin JS, le Riche WH, Kornaczewski A, Schmidt W, Rankin JG. Morbidity in alcoholics. Evidence for accelerated development of physical disease in women. Arch Intern Med. 1977;137(7):883–7. pmid:879927.
- 68. Pares A, Caballeria J, Bruguera M, Torres M, Rodes J. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol. 1986;2(1):33–42. pmid:3950362.
- 69. Marbet UA, Bianchi L, Meury U, Stalder GA. Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease. J Hepatol. 1987;4(3):364–72. pmid:3598164.
- 70. Morgan MY, Sherlock S. Sex-related differences among 100 patients with alcoholic liver disease. Br Med J. 1977;1(6066):939–41. pmid:851792; PubMed Central PMCID: PMCPMC1605784.
- 71. Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025–9. pmid:8621128.
- 72. Ikejima K, Enomoto N, Iimuro Y, Ikejima A, Fang D, Xu J, et al. Estrogen increases sensitivity of hepatic Kupffer cells to endotoxin. Am J Physiol. 1998;274(4 Pt 1):G669–76. pmid:9575848.
- 73. Kono H, Wheeler MD, Rusyn I, Lin M, Seabra V, Rivera CA, et al. Gender differences in early alcohol-induced liver injury: role of CD14, NF-kappaB, and TNF-alpha. Am J Physiol Gastrointest Liver Physiol. 2000;278(4):G652–61. pmid:10762620.
- 74. Loft S, Olesen KL, Dossing M. Increased susceptibility to liver disease in relation to alcohol consumption in women. Scand J Gastroenterol. 1987;22(10):1251–6. pmid:3433014.
- 75. Nanji AA, Jokelainen K, Fotouhinia M, Rahemtulla A, Thomas P, Tipoe GL, et al. Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines. Am J Physiol Gastrointest Liver Physiol. 2001;281(6):G1348–56. pmid:11705739.
- 76. Mezey E, Kolman CJ, Diehl AM, Mitchell MC, Herlong HF. Alcohol and dietary intake in the development of chronic pancreatitis and liver disease in alcoholism. Am J Clin Nutr. 1988;48(1):148–51. pmid:3389321.
- 77. Maher JJ. How does estrogen enhance endotoxin toxicity? Let me count the ways. Hepatology. 1998;28(6):1720–1. pmid:9828242.
- 78. Schenker S, Bay MK. Medical problems associated with alcoholism. Adv Intern Med. 1998;43:27–78. pmid:9506178.
- 79. Thurman RG. Sex-related liver injury due to alcohol involves activation of Kupffer cells by endotoxin. Can J Gastroenterol. 2000;14 Suppl D:129D–35D. pmid:11110625.
- 80. Gao B, Xu MJ, Bertola A, Wang H, Zhou Z, Liangpunsakul S. Animal Models of Alcoholic Liver Disease: Pathogenesis and Clinical Relevance. Gene Expr. 2017;17(3):173–86. pmid:28411363; PubMed Central PMCID: PMCPMC5500917.
- 81. Enomoto N, Yamashina S, Schemmer P, Rivera CA, Bradford BU, Enomoto A, et al. Estriol sensitizes rat Kupffer cells via gut-derived endotoxin. Am J Physiol. 1999;277(3 Pt 1):G671–7. pmid:10484393.